Page last updated: 2024-09-05

lapatinib and 2,4,3',5'-tetrahydroxystilbene

lapatinib has been researched along with 2,4,3',5'-tetrahydroxystilbene in 1 studies

Compound Research Comparison

Studies (lapatinib)	Trials (lapatinib)	Recent Studies (post-2010) (lapatinib)	Studies (2,4,3',5'-tetrahydroxystilbene)	Trials (2,4,3',5'-tetrahydroxystilbene)	Recent Studies (post-2010) (2,4,3',5'-tetrahydroxystilbene)
1,919	305	1,442	113	2	102

Protein Interaction Comparison

Protein	Taxonomy	lapatinib (IC50)	2,4,3',5'-tetrahydroxystilbene (IC50)
Hepatocyte growth factor receptor	Homo sapiens (human)		5.15

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Akl, MR; Ayoub, NM; Ebrahim, HY; El Sayed, KA; Goda, AA; Hananeh, WM; Liu, YY; Meyer, SA; Mohyeldin, MM; Nagumalli, SK; Siddique, AB	1

Other Studies

1 other study(ies) available for lapatinib and 2,4,3',5'-tetrahydroxystilbene

Article	Year
(-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo. Nutrients, 2019, Feb-15, Volume: 11, Issue:2 Topics: Aldehydes; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cyclopentane Monoterpenes; Drug Therapy, Combination; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Humans; Lapatinib; Mice; Phenols; Receptor, ErbB-2	2019

Article

Year

(-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.

Nutrients, 2019, Feb-15, Volume: 11, Issue:2

Topics: Aldehydes; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cyclopentane Monoterpenes; Drug Therapy, Combination; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Humans; Lapatinib; Mice; Phenols; Receptor, ErbB-2

2019